Inari Medical PEERLESS Results Show Superiority Of FlowTriever Compared To Catheter-Directed Thrombolytics For Intermediate-Risk Pulmonary Embolism, Published In 'Circulation'; PEERLESS Met Its Primary Composite Endpoint
Inari Medical PEERLESS Results Show Superiority Of FlowTriever Compared To Catheter-Directed Thrombolytics For Intermediate-Risk Pulmonary Embolism, Published In 'Circulation'; PEERLESS Met Its Primary Composite Endpoint
Inari Medical, Inc. (NASDAQ:NARI) ("Inari"), a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced positive results from the prospective PEERLESS Randomized Controlled Trial (RCT) comparing FlowTriever to catheter-directed thrombolytics (CDT). The results were presented by Dr. Wissam Jaber, Professor of Medicine at Emory University School of Medicine and Co-Global Principal Investigator (PI), during the Late-Breaking Clinical Trial Session at the 2024 Transcatheter Cardiovascular Therapeutics (TCT) Annual Scientific Symposium in Washington, D.C. In recognition of the clinical relevance of the study, results were also simultaneously published in Circulation, the premier peer-reviewed journal of the American Heart Association (AHA).
Inari Medical, Inc.（納斯達克：NARI）（「Inari」）是一家致力於治療和改善患有靜脈和其他疾病患者生活的醫療器械公司，今天宣佈了前瞻性PEERLESS隨機對照試驗（RCT）的積極結果，比較了FlowTriever和導管直接溶栓（CDT）。這些結果由埃默裏大學醫學院醫學教授、聯合全球首席研究員（PI）之一Wissam Jaber博士在2024年轉導介入心血管治療（TCT）年度科學研討會的最新臨床試驗分會上在華盛頓特區宣佈。爲了表彰該研究的臨床重要性，結果同時發表在美國心臟協會（AHA）的權威同行評審期刊Circulation上。
PEERLESS met its primary composite endpoint (win ratio 5.01, p<0.001), driven by patients experiencing significantly fewer clinical deteriorations or therapy escalations, fewer ICU admissions, and shorter ICU lengths of stay with FlowTriever versus CDT. Patients also had faster recovery of clinical symptoms and hemodynamics, shorter hospital length of stay, and fewer 30-day readmissions.
PEERLESS實現了其主要的綜合終點（勝率5.01，p
譯文內容由第三人軟體翻譯。
